Abbott, Insulet on ‘pay-as-you-go’ automated insulin delivery system

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Gam1983)
(Image: Getty/Gam1983)

Related tags: Abbott, Insulin, Diabetes, Digital health

Abbott’s glucose sensing technology and a tubeless insulin delivery system developed by Insulet are set to create a personalized diabetes management solution.

A partnership between delivery technologies developer, Insulet, and Abbott will see the companies integrate their respective developments, Omnipod Horizon automated insulin delivery system and FreeStyle Libre glucose level sensor, into one system.

The result will be a solution where the required quantity of insulin for the patient will be calculated based on the glucose data captured by the sensor, and automatically adjusted in the delivery pod and administered to the patient.

Insulin quantity calculation will be processed via an algorithm embedded in the Omnipod system, once the data is transmitted by the sensor.

The platform will be designed to remain in automated insulin delivery mode; however, it will be connected to and controllable via an application for smartphones, allowing the user to manually take insulin doses, if needed.

According to Abbott, this integrated system will be the first combined system with a fully disposable wearable sensor and pump, and is expected to offer significant benefits to patients, such as ease of use and convenience due to dosing accuracy and simplicity.

Moreover, users will ultimately benefit from ease of obtaining supplies with this ‘pay-as-you-go’ insulin administration model, eliminating product wastage, Abbott stated.

Connected approaches to improve diabetes management are currently in the spotlight for manufacturers, “as diabetes care becomes more interoperable,”​ commented Jared Watkin, Diabetes Care SVP of Abbott.

This latest partnership follows a collaboration of Abbott with Sanofi​, which saw the companies work jointly to integrate the glucose monitoring system with the latter’s insulin pens.

Ease of use in device manufacturing,​ as well as integration of digital technologies,​ are becoming increasingly important due to the prevalence of chronic diseases such as diabetes, with manufacturers looking for ways​ to make the delivery of such treatments more convenient.

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Follow us

Products

View more

Webinars